Treatment and prevention of invasive pneumococcal disease

A R Domínguez-Alegría; V Pintado; I Barbolla

doi:10.1016/j.rce.2018.01.004

Treatment and prevention of invasive pneumococcal disease

Rev Clin Esp (Barc). 2018 Jun-Jul;218(5):244-252. doi: 10.1016/j.rce.2018.01.004. Epub 2018 Feb 12.

[Article in English, Spanish]

Authors

A R Domínguez-Alegría¹, V Pintado², I Barbolla³

Affiliations

¹ Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, España. Electronic address: alegria.rda@gmail.com.
² Servicio de Enfermedades Infecciosas, Hospital Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, España.
³ Servicio de Medicina Interna, Hospital Ramón y Cajal, Madrid, España.

PMID: 29448981
DOI: 10.1016/j.rce.2018.01.004

Abstract

Invasive pneumococcal disease is a severe infection that mainly affects patients with associated comorbidity. The paediatric conjugate vaccination has resulted in a change in the adult vaccination strategy. The antibiotic resistance of pneumococcus is not currently a severe problem. Nevertheless, the World Health Organisation has included pneumococcus among the bacteria whose treatment requires the introduction of new drugs, such as ceftaroline and ceftobiprole. Although the scientific evidence is still limited, the combination of beta-lactams and macrolides is recommended as empiric therapy for bacteraemic pneumococcal pneumonia.

Keywords: Combined therapy; Enfermedad neumocócica invasiva; Invasive pneumococcal disease; Resistance; Resistencia; Streptococcus pneumoniae; Terapia combinada; Vaccine; Vacuna.